Developer docs
API playgroundTry for free, no card

Search company profiles

MAK Capital

Full company profile

uuid000a1xa

Namestring
MAK Capital
Legal namestring
MAK Capital One LLC
Company typeenum
Private
Founded yearint
2001
Descriptiontext

MAK Capital is a privately held, New York-based activist investment fund operating as MAK Capital One LLC. Founded in 2001 and staffed by an 11–50-person team led by CEO Michael Kaufman and Managing Director Craig Nemiroff, the firm pursues a fundamental, opportunistic investment strategy targeting companies it views as undervalued or operationally inefficient. Its published differentiation rests on shareholder activism — engaging portfolio companies to drive strategic changes, board appointments, cost optimization, and value-unlocking transactions such as spin-offs and listings.

The firm's current disclosed activity is concentrated in life sciences. It led a $40 million Series B financing for Trailhead Biosystems, an Ohio-based Cleveland Clinic spinout that uses robotic platforms to manufacture human iPSC-derived cells for pharmaceutical testing. It simultaneously holds a 7% stake in German biotech Evotec SE and has entered a cooperation agreement with the company that includes nominating Wolfgang Hofmann to the supervisory board, demanding accelerated cost reductions following an ~85% five-year share-price decline, and pressing for the US listing of Evotec's Seattle subsidiary Just Biologics at an implied valuation exceeding €1 billion. It also discloses a 6.3% passive stake in US neurosurgery device company ClearPoint Neuro via an SEC Schedule 13G/A filing.

As a private fund vehicle, MAK Capital does not sell products to end customers; interests in the underlying fund are offered only to qualified investors under Section 4(2) of the Securities Act and Rule 506 of Regulation D (and equivalent non-US exemptions under Regulation S), with no public AUM, fee schedule, or revenue disclosure in the source material. The firm's economics therefore derive from conventional management- and performance-based fees on committed LP capital, with the underlying revenue mechanics opaque from available data.

Short descriptiontext

MAK Capital is a privately held, New York-based activist investment fund founded in 2001 that pursues fundamental, opportunistic investments in undervalued public and private companies, currently focused on life-sciences names including Trailhead Biosystems, Evotec SE, and ClearPoint Neuro.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
activist investment, equity investment, shareholder activism, value investing, biotech investment
Industry3 codes
1Alternative Investments for Private Wealth (Hedge Funds, PE/VC Access, Private Credit)
CodeFSAAABAIPrimaryYes
2Equity Capital Advisory (Private Equity Placements, Growth Capital)
CodeBPAHAOAEPrimaryNo
3Capital Raising Advisory (Equity & Equity-Linked)
CodeFSAEAGACPrimaryNo
NAICS code3 codes
  • Portfolio Management and Investment Advice52394
  • Portfolio Management and Investment Advice523940
  • Other Financial Investment Activities5239
SIC code2 codes
  • Investment Advice6282
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Activist Investment Management
No data
Cost components5 values
Personnel, Operations, Others, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

MAK Capital operates as an activist investment fund that acquires significant equity stakes in publicly traded companies, primarily in the biotechnology sector, and engages in shareholder activism to drive value creation. The fund pursues operational restructuring, board appointments, cost-cutting initiatives, and strategic transactions such as spin-offs and subsidiary listings, with interests offered to qualified investors under private placement exemptions.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1MAK Capital Activist Investment Fund
CategoryInvestment Management
Description

Privately offered activist equity investment fund that acquires significant stakes in underperforming public companies and pursues shareholder activism, operational restructuring, board changes, and strategic transactions to generate returns for qualified investors.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Largest and most established activist hedge fund globally, taking concentrated public-company positions and pushing for operational and governance changes - directly comparable activist playbook to MAK Capital but at significantly greater scale.

TypeDirect peer
Description

Activist fund focused on small-to-mid cap US public companies, advocating for board change, cost cuts, and strategic reviews - operates with a similar targeted, high-conviction activist approach to MAK Capital.

TypeDirect peer
Description

Activist fund that takes meaningful minority stakes and works constructively with management on strategy - directly comparable activist philosophy to MAK Capital, often engaging on board appointments and capital allocation.

TypeBroad incumbent
Description

Iconic activist investor taking controlling or influential positions and publicly agitating for change - a longer-tenured, more confrontational version of MAK Capital's activist model.

TypeBroad incumbent
Description

Concentrated, high-conviction activist fund led by Bill Ackman - operates with similar targeted activist campaigns but at a much larger AUM scale than MAK Capital.

TypeDirect peer
Description

Activist fund focused on constructive engagement with portfolio companies on operational improvement and capital allocation - directly comparable mid-sized activist strategy to MAK Capital.

TypeDirect peer
Description

Activist fund focused on event-driven situations and constructive engagement with portfolio companies - similar profile to MAK Capital in size and approach, with comparable shareholder activism playbook.

TypeDirect peer
Description

Smaller, focused activist fund taking stakes in undervalued small/mid-cap companies and pushing for strategic change - directly comparable in size and activism approach to MAK Capital.

TypeDirect peer
Description

Activist fund focused on consumer and tech sectors, taking meaningful stakes and engaging with management - similar mid-sized activist profile to MAK Capital.

TypeDirect peer
Description

Smaller activist fund focused on small/mid-cap companies, often collaborating with other activists - similar size and approach to MAK Capital's activism model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment6 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MAK Capital

Activist Investment Managementmakcapitalfund.com

MAK Capital is a privately held, New York-based activist investment fund founded in 2001 that pursues fundamental, opportunistic investments in undervalued public and private companies, currently focused on life-sciences names including Trailhead Biosystems, Evotec SE, and ClearPoint Neuro.

What MAK Capital does

MAK Capital is a privately held, New York-based activist investment fund operating as MAK Capital One LLC. Founded in 2001 and staffed by an 11–50-person team led by CEO Michael Kaufman and Managing Director Craig Nemiroff, the firm pursues a fundamental, opportunistic investment strategy targeting companies it views as undervalued or operationally inefficient. Its published differentiation rests on shareholder activism — engaging portfolio companies to drive strategic changes, board appointments, cost optimization, and value-unlocking transactions such as spin-offs and listings.

The firm's current disclosed activity is concentrated in life sciences. It led a $40 million Series B financing for Trailhead Biosystems, an Ohio-based Cleveland Clinic spinout that uses robotic platforms to manufacture human iPSC-derived cells for pharmaceutical testing. It simultaneously holds a 7% stake in German biotech Evotec SE and has entered a cooperation agreement with the company that includes nominating Wolfgang Hofmann to the supervisory board, demanding accelerated cost reductions following an ~85% five-year share-price decline, and pressing for the US listing of Evotec's Seattle subsidiary Just Biologics at an implied valuation exceeding €1 billion. It also discloses a 6.3% passive stake in US neurosurgery device company ClearPoint Neuro via an SEC Schedule 13G/A filing.

As a private fund vehicle, MAK Capital does not sell products to end customers; interests in the underlying fund are offered only to qualified investors under Section 4(2) of the Securities Act and Rule 506 of Regulation D (and equivalent non-US exemptions under Regulation S), with no public AUM, fee schedule, or revenue disclosure in the source material. The firm's economics therefore derive from conventional management- and performance-based fees on committed LP capital, with the underlying revenue mechanics opaque from available data.

MAK Capital firmographics

Firmographics
Name
MAK Capital
Legal name
MAK Capital One LLC
Website
https://makcapitalfund.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
11–50 employees
Short description
MAK Capital is a privately held, New York-based activist investment fund founded in 2001 that pursues fundamental, opportunistic investments in undervalued public and private companies, currently focused on life-sciences names including Trailhead Biosystems, Evotec SE, and ClearPoint Neuro.
Ownership category
akta.pro rank

MAK Capital industry classification

Industry
Product category
Activist Investment Management
NAICS
Portfolio Management and Investment Advice (52394), Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)
SIC
Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)
akta.pro primary industry
Alternative Investments for Private Wealth (Hedge Funds, PE/VC Access, Private Credit) (FSAAABAI)
akta.pro secondary industries
Equity Capital Advisory (Private Equity Placements, Growth Capital) (BPAHAOAE), Capital Raising Advisory (Equity & Equity-Linked) (FSAEAGAC)

Keywords

  • Activist investment
  • Equity investment
  • Shareholder activism
  • Value investing
  • Biotech investment

Where MAK Capital is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

MAK Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Others, Marketing or Sales, Technology or R&D

MAK Capital product offering

Product offering

Core offering

MAK Capital operates as an activist investment fund that acquires significant equity stakes in publicly traded companies, primarily in the biotechnology sector, and engages in shareholder activism to drive value creation. The fund pursues operational restructuring, board appointments, cost-cutting initiatives, and strategic transactions such as spin-offs and subsidiary listings, with interests offered to qualified investors under private placement exemptions.

Differentiator

Problem solved

Functional benefit

Products and services

  • MAK Capital Activist Investment Fund Privately offered activist equity investment fund that acquires significant stakes in underperforming public companies and pursues shareholder activism, operational restructuring, board changes, and strategic transactions to generate returns for qualified investors.

Companies that use MAK Capital

Customer profile

Ideal customer profiles1 record

MAK Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

MAK Capital partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

MAK Capital competitors and assessment

Company assessment

Broad incumbents

  • Elliott Investment Management: Largest and most established activist hedge fund globally, taking concentrated public-company positions and pushing for operational and governance changes - directly comparable activist playbook to MAK Capital but at significantly greater scale.
  • Icahn Enterprises: Iconic activist investor taking controlling or influential positions and publicly agitating for change - a longer-tenured, more confrontational version of MAK Capital's activist model.
  • Pershing Square Capital Management: Concentrated, high-conviction activist fund led by Bill Ackman - operates with similar targeted activist campaigns but at a much larger AUM scale than MAK Capital.

Direct peers

  • Starboard Value: Activist fund focused on small-to-mid cap US public companies, advocating for board change, cost cuts, and strategic reviews - operates with a similar targeted, high-conviction activist approach to MAK Capital.
  • ValueAct Capital: Activist fund that takes meaningful minority stakes and works constructively with management on strategy - directly comparable activist philosophy to MAK Capital, often engaging on board appointments and capital allocation.
  • Trian Fund Management: Activist fund focused on constructive engagement with portfolio companies on operational improvement and capital allocation - directly comparable mid-sized activist strategy to MAK Capital.
  • Jana Partners: Activist fund focused on event-driven situations and constructive engagement with portfolio companies - similar profile to MAK Capital in size and approach, with comparable shareholder activism playbook.
  • Engine Capital: Smaller, focused activist fund taking stakes in undervalued small/mid-cap companies and pushing for strategic change - directly comparable in size and activism approach to MAK Capital.
  • H Partners Management: Activist fund focused on consumer and tech sectors, taking meaningful stakes and engaging with management - similar mid-sized activist profile to MAK Capital.
  • Legion Partners Asset Management: Smaller activist fund focused on small/mid-cap companies, often collaborating with other activists - similar size and approach to MAK Capital's activism model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

MAK Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MAK Capital leadership team

Management profile

Number of profiles

Profiles2 records

MAK Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MAK Capital M&A and investment

M&A and investment

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MAK Capital

What does MAK Capital do?

MAK Capital operates as an activist investment fund that acquires significant equity stakes in publicly traded companies, primarily in the biotechnology sector, and engages in shareholder activism to drive value creation. The fund pursues operational restructuring, board appointments, cost-cutting initiatives, and strategic transactions such as spin-offs and subsidiary listings, with interests offered to qualified investors under private placement exemptions.

Is MAK Capital a public or private company?

MAK Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was MAK Capital founded?

MAK Capital was founded in 2001. It employs 11 to 50 people.

Where is MAK Capital based?

MAK Capital is headquartered in New York, United States, in the North America region.

Who are MAK Capital's main competitors?

Broad incumbents on record are Elliott Investment Management, Icahn Enterprises and Pershing Square Capital Management. Direct peers are Starboard Value, ValueAct Capital, Trian Fund Management, Jana Partners, Engine Capital, H Partners Management and Legion Partners Asset Management.

Does MAK Capital have an API?

No public API is recorded for MAK Capital.

What industry is MAK Capital in?

MAK Capital's product category is Activist Investment Management. Its primary akta.pro industry code is FSAAABAI, Alternative Investments for Private Wealth (Hedge Funds, PE/VC Access, Private Credit), with a secondary code of BPAHAOAE, Equity Capital Advisory (Private Equity Placements, Growth Capital). Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AD HOC NEWSClearPoint Neuro stock (US18507C1099): MAK Capital discloses 6.3% passive stake in CLPTMAK Capital and related entities disclosed a 6.3% passive stake in ClearPoint Neuro, Inc. through an SEC Schedule 13G/A filing, reporting beneficial ownership of approximately 1.9 million common shares as of May 15, 2026. The filing is classified as passive, indicating the institutional investor does not currently intend to seek control or influence management. The disclosure signals renewed institutional interest in the MRI-guided neurosurgery technology company amid notable share price volatility.pegnCourt grants Oncoclínicas temporary protection from creditorsOncoclínicas obtained a 60-day stay on debt enforcement from São Paulo's bankruptcy court, with creditors including Caixa, Itaú, and Bradesco. The court also approved a R$150 million loan from asset managers Mak Capital and Lumina, contingent on a board reshuffle. The funding aims to stabilize supply chains and support a potential R$500 million capital injection.The Rio TimesOncoclínicas Loses Its Entire Board — and Has 15 Days of Cash LeftOncoclínicas, Latin America's largest private cancer network, lost its entire board of directors on April 7 after chair Marcelo Gasparino da Silva resigned, triggering automatic dissolution under Brazil's voto múltiplo rules. The company is facing severe financial distress with approximately 15 days of operating cash remaining and has delayed treatments for roughly 3,000 cancer patients due to an inability to pay for medications. Three competing rescue proposals are now on the table, with Mak Capital offering R$500 million, Starboard proposing R$1 billion in debt-to-equity conversion with Fleury as co-investor, and the earlier Porto Seguro NewCo deal, while the stock surged 10% on news that board removal may clear the path for restructuring.BloombergMAK Capital Tells Evotec to List US Unit Worth Over €1 billionActivist fund MAK Capital, which holds a 7% stake in German biotech firm Evotec SE, has urged the company to list its Seattle-based US subsidiary Just Biologics on a US exchange, arguing it would command a valuation exceeding €1 billion ($1.2 billion) and access a deeper investor base. MAK Capital also called for accelerated cost-cutting measures after Evotec shares lost approximately 85% of their value over the past five years and the company's market cap fell to around €801 million. Additionally, MAK proposed appointing former Novartis and Fresenius executive Wolfgang Hofmann to Evotec's supervisory board.PR NewswireTrailhead Biosystems Expands Financing to $40 MillionTrailhead Biosystems Inc. has added $20 million in new funding, expanding its total financing to $40 million, with the round led by MAK Capital. The additional capital will accelerate commercialization of the company's iPSC-derived human cell products and custom differentiation services for preclinical research and drug discovery. The funding will also support investments in manufacturing processes, quality systems, and operational infrastructure.PR NewswireTrailhead Biosystems Secures $20 Million to Drive Innovation and Accelerate GrowthTrailhead Biosystems secured $20 million in financing led by MAK Capital to expand its iPSC differentiation platform. The funding will support personnel, manufacturing, and partnerships, with upcoming products including pancreatic islets and dopaminergic neurons. The company aims to strengthen therapeutic partnerships and advance cell-based therapies.